Propanc Biopharma Files S-1 with SEC

TL;DR

Propanc Biopharma dropped an S-1 filing on 10/30/24 - check financials for the FY ending 6/30/24.

AI Summary

Propanc Biopharma, Inc. filed an S-1 form on October 30, 2024, detailing its financial status and business operations. The company, incorporated in Delaware with its principal executive offices in Camberwell, Victoria, Australia, operates in the pharmaceutical preparations sector. The filing covers the fiscal year ending June 30, 2024, and includes financial data from previous fiscal years.

Why It Matters

This S-1 filing provides crucial insights into Propanc Biopharma's financial health and strategic direction, which is essential for investors and stakeholders to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1, Propanc Biopharma is likely seeking to raise capital or undergo a significant corporate event, which inherently carries risks related to market conditions, regulatory approvals, and clinical trial outcomes.

Key Numbers

• FY 2024 — Fiscal Year End (The S-1 filing covers financial data up to June 30, 2024.)
• FY 2023 — Previous Fiscal Year End (Comparative financial data from the previous fiscal year ending June 30, 2023, is included.)
• FY 2022 — Prior Fiscal Year End (Financial data from the fiscal year ending June 30, 2022, is also referenced.)

Key Players & Entities

• Propanc Biopharma, Inc. (company) — Filer of the S-1 document
• 0001493152-24-042965 (dollar_amount) — Accession number for the filing
• 20241030 (date) — Filing date
• 2834 (dollar_amount) — Standard Industrial Classification for Pharmaceutical Preparations
• 330662986 (dollar_amount) — IRS Number
• DE (company) — State of Incorporation
• 0630 (date) — Fiscal Year End
• 333-282886 (dollar_amount) — SEC File Number
• 241407364 (dollar_amount) — Film Number
• 61-03-9882-0780 (dollar_amount) — Business Phone Number

FAQ

Key Financial Figures

• $0.001 — of one share of common stock, par value $0.001 ("Common Stock") of Propanc Biopharma,
• $0.00035 — r Common Stock as quoted on the OTC was $0.00035 ($21.00 assuming a reverse stock split
• $21.00 — tock as quoted on the OTC was $0.00035 ($21.00 assuming a reverse stock split of 1-for
• $250 m — public common equity float of more than $250 million, or (ii) we have annual revenues
• $100 million — ntly completed fiscal year of more than $100 million plus we have a public common equity flo
• $700 million — uity float or public float of more than $700 million. We also would not be eligible for stat
• $0.01 — red stock, 1,500,005 shares authorized, $0.01 par value: Series B preferred stock,

Filing Documents

• forms-1.htm (S-1) — 2976KB
• ex23-1.htm (EX-23.1) — 5KB
• ex107.htm (EX-FILING FEES) — 21KB
• logo_001.jpg (GRAPHIC) — 67KB
• 0001493152-24-042965.txt ( ) — 12730KB
• ppcb-20240630.xsd (EX-101.SCH) — 75KB
• ppcb-20240630_cal.xml (EX-101.CAL) — 80KB
• ppcb-20240630_def.xml (EX-101.DEF) — 393KB
• ppcb-20240630_lab.xml (EX-101.LAB) — 605KB
• ppcb-20240630_pre.xml (EX-101.PRE) — 495KB
• forms-1_htm.xml (XML) — 1807KB

Risk Factors

Risk Factors 7 Cautionary Note Regarding Forward-Looking Statements 7

Use of Proceeds

Use of Proceeds 31 Market for Our Common Stock and Related Stockholder Matters 31 Capitalization 33

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35

Business

Business 41 Management 59

Executive Compensation

Executive Compensation 63 Description of Our Securities 69 Shares Eligible for Future Sale 74 Material U.S. Federal Income Tax Considerations 75

Underwriting

Underwriting 80 Legal Matters 87 Experts 87 Where You Can Find More Information 87 Through and including __________________ , 2024 (the 25 th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriter and with respect to their unsold allotments or subscriptions. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the shares of Common Stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. You should rely only on the information contained in this prospectus. Neither we nor the Underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus we have prepared. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. You should also read this prospectus together with the additional information described under " Where You Can Find More Information ." Unless the context otherwise requires, we use the terms "we," "us," "Company," "Propanc Biopharma," and "our" to refer to Propanc Biopharma, Inc. and its consolidated subsidiaries. Solely for convenience, our trademarks and tradenames referred to in this prospectus, may appear without the or symbols, b

View Full Filing

View this S-1 filing on SEC EDGAR